AR061840A1 - Compuestos fosfinatos antivirales - Google Patents
Compuestos fosfinatos antiviralesInfo
- Publication number
- AR061840A1 AR061840A1 ARP070103031A ARP070103031A AR061840A1 AR 061840 A1 AR061840 A1 AR 061840A1 AR P070103031 A ARP070103031 A AR P070103031A AR P070103031 A ARP070103031 A AR P070103031A AR 061840 A1 AR061840 A1 AR 061840A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally
- och2p
- substituted
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical class [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- -1 imido Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 229910052794 bromium Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052740 iodine Inorganic materials 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004421 aryl sulphonamide group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229940124530 sulfonamide Drugs 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 125000005421 aryl sulfonamido group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1) o una sal aceptable para uso farmacéutico o un profármaco del mismo, donde: R1 se selecciona independientemente de H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, heterociclo, halogeno, haloalquilo, alquilsulfonamido, arilsulfonamido, -C(O)NHS(O)2 o -S(O)2-, opcionalmente sustituido con uno o más A3; R2 se selecciona de: a) -C(Y1)(A3), b) alquilo C2-10, cicloalquilo C3-7 o alquil C1-4-cicloalquilo C3-7, donde dicho cicloalquilo y alquil-cicloalquilo pueden estar opcionalmente mono-, di- o tri-sustituido con alquilo C1-3 o donde dicho alquilo, cicloalquilo y alquil-cicloalquilo pueden estar opcionalmente mono- o di-sustituidos con sustituyentes seleccionados de hidroxi y O- alquilo C1-4 o donde cada uno de dichos grupos alquilo puede estar opcionalmente mono-, di- o tri-sustituido con halogeno, o donde cada uno de dichos grupos cicloalquilo es de 5, 6 o 7 miembros, uno o dos grupos -CH2- que no están unidos directamente entre si pueden estar opcionalmente sustituidos o reemplazados por -O- de modo que el átomo de O esté unido al átomo de N al cual R2 está unido por medio de por lo menos dos átomos de C, c) fenilo, alquil C1-3-fenilo, heteroarilo o alquil C1-3-heteroarilo, donde los grupos heteroarilo son de 5 o 6 miembros que tienen de 1 a 3 heteroátomos seleccionados de N, O y S, donde dichos grupos fenilo y heteroarilo pueden estar opcionalmente mono-, di- o tri-sustituidos con sustituyentes seleccionados de halogeno, -OH, alquilo C1-4, O-alquilo C1-4, S-alquilo C1-4, -NH2, -CF3, -NH(alquilo C1-4) y -N(alquilo C1-4)2, -CONH2 y -CONH-alquilo C1-4; y donde dicho alquilo C1-3 puede estar opcionalmente sustituido con uno o más halogenos; o d) -S(O)2(A3); R3 es H o alquilo C1-6; Y1 es Independientemente O, S, N(A3), N(O)(A3), N(OA3), N(O)(OA3) o N(N(A3)(A3)); Z es O, S o NR3; Z1 se selecciona entre las estructuras del grupo de formula (2); Ra es H o alcoxi C1-6; Rb es H, F, CI, Br, I o alquilo C1-6; Rc es H, ciano, F, CI, Br, I, -C(=O)NRdRe, alcoxi C1-6 o fenilo que está opcionalmente sustituido con uno o más F, CI, Br, I, alquilo C1-6 o alcoxi C1-6; Rd y Re son independientemente H o alquilo C1-6; cada L es independientemente CH o N; Z2a es H, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, donde cualquier átomo de carbono puede ser opcionalmente reemplazado con un heteroátomo seleccionado de O, S o N, o Z2a opcionalmente forma un heterociclo con uno o más R1, R2, Q1 o A3; Z2b es H, alquilo C1-6, alquenilo C2-8, alquinilo C2-8; Q1 es alquilo C1-8, alquenilo C2-8 o alquinilo C2-8; o Q1 y Z2a tomados junto con los átomos a los cuales están unidos forman un heterociclo, heterociclo que puede opcionalmente estar sustituido con uno o más oxo (=O) o A3; A3 se selecciona independientemente de PRT, H, -OH, -C(O)OH, ciano, alquilo, alquenilo, alquinilo, amino, amido, imido, imino, halogeno, CF3, CH2CF3, cicloalquilo, nitro, arilo, aralquilo, alcoxi, ariloxi, heterociclo, -C(A2)3, -C(A2)2-C(O)A2, -C(O)A2, -C(O)OA2, -O(A2), -N(A2)2, -S(A2), -CH2P(Y1)(A2)(OA2), -CH2P(Y1)(A2)(N(A2)2), -CH2P(Y1)(OA2)(OA2), -OCH2P(Y1)(OA2)(OA2), -OCH2P(Y1)(A2)(OA2), -OCH2P(Y1)(A2)(N(A2)2), - C(O)OCH2P(Y1)(OA2)(OA2), -C(O)OCH2P(Y1)(A2)(OA2), -C(O)OCH2P(Y1)(A2)(N(A2)2), -CH2P(Y1)(OA2)(N(A2)2), -OCH2P(Y1)(OA2)(N(A2)2), -C(O)OCH2P(Y1)(OA2)(N(A2)2), -CH2P(Y1)(N(A2)2)(N(A2)2), -C(O)OCH2P(Y1)(N(A2)2)(N(A2)2), OCH2P(Y1)(N(A2)2)(N(A2)2), -(CH2)m- heterociclo, -(CH2)m-C(O)O-alquilo, -O-(CH2)m-O-C(O)-O-alquilo, -O-(CH2)r-O-C(O)-(CH2)m-alquilo, (CH2)m-O-C(O)-O-alquilo, (CH2)mO-C(O)-O-cicloalquilo, -N(H)C(Me)C(O)O-alquilo o alcoxi arilsulfonamida, donde cada A3 puede estar opcionalmente sustituido con 1 a 4 -R1, -P(Y1)(OA2)(OA2), -P(Y1)(OA2)(N(A2)2), -P(Y1)(A2)(OA2), -P(Y1)(A2)(N(A2)2), o P(Y1)(N(A2)2)(N(A2)2), -C(=O)N(A2)2), halogeno, alquilo, alquenilo, alquinilo, arilo, carbociclo, heterociclo, aralquilo, arilsulfonamida, arilalquilsulfonamida, ariloxi sulfonamida, ariloxi alquilsulfonamida, ariloxi arilsulfonamida, alquil sulfonamida, alquiloxi sulfonamida, alquiloxi alquilsulfonamida, ariltio, -(CH2)m-heterociclo, -(CH2)m-C(O)O-alquilo, -O(CH2)m-OC(O)O-alquilo, -O- (CH2)m-O-C(O)-(CH2)m-alquilo, -(CH2)m-O-C(O)-O-alquilo, -(CH2)m-O-C(O)O-cicloalquilo, -N(H)C(CH3)C(O)O-alquilo, o alcoxi arilsulfonamido, opcionalmente sustituidos con R1; opcionalmente cada caso independiente de A3 y Q1 se puede tomar junto con uno o más grupos A3 o Q1 para formar un anillo; A2 se selecciona independientemente de PRT, H, alquilo, alquenilo, alquinilo, amino, aminoácido, alcoxi, ariloxi, ciano, haloalquilo, cicloalquilo, arilo, heteroarilo, alquilsulfonamida, o arilsulfonamida, opcionalmente sustituido con A3; y m es 0 a 6; con la condicion de que el compuesto no sea un compuesto de ninguna de las formulas de la Tabla (3).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81948806P | 2006-07-07 | 2006-07-07 | |
| US83290806P | 2006-07-24 | 2006-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061840A1 true AR061840A1 (es) | 2008-09-24 |
Family
ID=38626760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103031A AR061840A1 (es) | 2006-07-07 | 2007-07-06 | Compuestos fosfinatos antivirales |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US7893264B2 (es) |
| EP (2) | EP2422791B1 (es) |
| JP (3) | JP2009542698A (es) |
| KR (1) | KR20090026216A (es) |
| CN (1) | CN102532198A (es) |
| AR (1) | AR061840A1 (es) |
| AT (1) | ATE554776T1 (es) |
| AU (1) | AU2007269567B2 (es) |
| BR (1) | BRPI0713961A2 (es) |
| CA (1) | CA2656356C (es) |
| EA (1) | EA018098B1 (es) |
| ES (2) | ES2388969T3 (es) |
| HK (1) | HK1127295A1 (es) |
| HR (1) | HRP20090076A2 (es) |
| IL (1) | IL195489A0 (es) |
| MX (1) | MX2009000236A (es) |
| NO (1) | NO20090596L (es) |
| TW (1) | TW200819460A (es) |
| WO (1) | WO2008005565A2 (es) |
| ZA (1) | ZA200810400B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| CA2656356C (en) * | 2006-07-07 | 2013-04-09 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
| SG175692A1 (en) * | 2008-04-15 | 2011-11-28 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| WO2010101967A2 (en) * | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
| WO2010151472A1 (en) * | 2009-06-23 | 2010-12-29 | Gilead Sciences, Inc. | Combination of a ns5b polymerase inhibitor and a hcv ns3 protease inhibitor for the treatment of hcv |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2011156757A1 (en) * | 2010-06-10 | 2011-12-15 | Gilead Sciences, Inc. | Combination of anti-hcv compounds with ribavirin for the treatment of hcv |
| CA2822037A1 (en) * | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Methods for treating hcv |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
| ES2527510T1 (es) | 2011-10-21 | 2015-01-26 | Abbvie Inc. | Métodos para el tratamiento del VHC que comprenden al menos dos agentes antivirales de acción directa, ribavirina pero no interferón |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE112012003457T5 (de) | 2011-10-21 | 2015-03-12 | Abbvie Inc. | Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV) |
| JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN104144682A (zh) | 2013-01-31 | 2014-11-12 | 吉利德法莫赛特有限责任公司 | 两个抗病毒化合物的联用制剂 |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN103539833B (zh) * | 2013-09-29 | 2016-02-03 | 北京林业大学 | 高活性α-葡萄糖苷酶抑制肽及其制备方法和用途 |
| CN103539831B (zh) * | 2013-09-29 | 2016-02-03 | 北京林业大学 | 山杏α-葡萄糖苷酶抑制肽及其制备方法和用途 |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| JP6770098B2 (ja) | 2016-05-27 | 2020-10-14 | ギリアード サイエンシーズ， インコーポレイテッド | Ｎｓ５ａ、ｎｓ５ｂまたはｎｓ３阻害剤を使用する、ｂ型肝炎ウイルス感染症を処置するための方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| WO1991019721A1 (en) | 1990-06-13 | 1991-12-26 | Arnold Glazier | Phosphorous produgs |
| DE69129650T2 (de) | 1990-09-14 | 1999-03-25 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
| DE4308096A1 (de) | 1993-03-13 | 1994-09-15 | Hoechst Ag | Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung |
| ATE199906T1 (de) | 1993-06-29 | 2001-04-15 | Mitsubishi Chem Corp | Phosphonat-nukleotid ester-derivate |
| DE69435319D1 (de) | 1993-09-17 | 2010-12-16 | Gilead Sciences Inc | Nukleotidanaloge |
| JPH07183249A (ja) | 1993-12-22 | 1995-07-21 | Nec Yamagata Ltd | イオン注入工程管理方法 |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US5968788A (en) * | 1995-08-28 | 1999-10-19 | Toray Industries, Inc. | Method for producing folic acid |
| US6004977A (en) * | 1996-12-27 | 1999-12-21 | Hoechst Marion Roussel, Inc. | N-(pyridinylamino) isoindolines and related compounds |
| DE19843360A1 (de) * | 1998-09-22 | 2000-03-30 | Hassan Jomaa | Phosphororganische Verbindungen und ihre Verwendung |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| JP4733023B2 (ja) | 2003-04-16 | 2011-07-27 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤 |
| AU2005274700B2 (en) | 2004-07-16 | 2011-11-10 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| MX2007012659A (es) | 2005-04-13 | 2008-01-11 | Astex Therapeutics Ltd | Derivados de hidroxi-benzamida y su uso como inhibidores de hsp90. |
| NZ594105A (en) * | 2005-07-25 | 2013-02-22 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| KR101381387B1 (ko) * | 2005-07-29 | 2014-04-11 | 메디비르 아베 | Ｃ형 간염 바이러스의 마크로사이클릭 억제제 |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2656356C (en) | 2006-07-07 | 2013-04-09 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| WO2010151472A1 (en) | 2009-06-23 | 2010-12-29 | Gilead Sciences, Inc. | Combination of a ns5b polymerase inhibitor and a hcv ns3 protease inhibitor for the treatment of hcv |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2007
- 2007-07-06 CA CA2656356A patent/CA2656356C/en not_active Expired - Fee Related
- 2007-07-06 AR ARP070103031A patent/AR061840A1/es not_active Application Discontinuation
- 2007-07-06 JP JP2009518397A patent/JP2009542698A/ja not_active Withdrawn
- 2007-07-06 ES ES07796752T patent/ES2388969T3/es active Active
- 2007-07-06 BR BRPI0713961-6A patent/BRPI0713961A2/pt not_active IP Right Cessation
- 2007-07-06 US US11/825,606 patent/US7893264B2/en active Active
- 2007-07-06 ES ES11190674T patent/ES2531315T3/es active Active
- 2007-07-06 TW TW096124722A patent/TW200819460A/zh unknown
- 2007-07-06 AT AT07796752T patent/ATE554776T1/de active
- 2007-07-06 WO PCT/US2007/015664 patent/WO2008005565A2/en active Application Filing
- 2007-07-06 EA EA200900154A patent/EA018098B1/ru not_active IP Right Cessation
- 2007-07-06 KR KR1020097002642A patent/KR20090026216A/ko not_active Application Discontinuation
- 2007-07-06 CN CN2011104294087A patent/CN102532198A/zh active Pending
- 2007-07-06 EP EP11190674.9A patent/EP2422791B1/en active Active
- 2007-07-06 AU AU2007269567A patent/AU2007269567B2/en not_active Ceased
- 2007-07-06 US US12/303,219 patent/US20090227491A1/en not_active Abandoned
- 2007-07-06 MX MX2009000236A patent/MX2009000236A/es active IP Right Grant
- 2007-07-06 EP EP07796752A patent/EP2043658B1/en active Active
-
2008
- 2008-11-25 IL IL195489A patent/IL195489A0/en unknown
- 2008-12-09 ZA ZA2008/10400A patent/ZA200810400B/en unknown
-
2009
- 2009-02-06 HR HR20090076A patent/HRP20090076A2/xx not_active Application Discontinuation
- 2009-02-06 NO NO20090596A patent/NO20090596L/no not_active Application Discontinuation
- 2009-07-16 HK HK09106472.5A patent/HK1127295A1/xx not_active IP Right Cessation
-
2010
- 2010-10-27 US US12/913,704 patent/US8586744B2/en active Active
- 2010-10-27 US US12/913,692 patent/US8674088B2/en active Active
-
2012
- 2012-02-28 JP JP2012041605A patent/JP2012107061A/ja not_active Withdrawn
-
2015
- 2015-01-22 JP JP2015010367A patent/JP6010640B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061840A1 (es) | Compuestos fosfinatos antivirales | |
| AR054837A1 (es) | Compuestos inhibidores del virus de la hepatitis c | |
| AR068794A1 (es) | Compuestos antivirales | |
| AR054838A1 (es) | Compuestos inhibidores del virus de la hepatitis c | |
| AR067180A1 (es) | Compuestos antivirales | |
| AR050174A1 (es) | Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas | |
| AR048004A1 (es) | Nuevos esteres de quinuclidina cuaternizados | |
| AR079689A1 (es) | Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias. | |
| AR074109A1 (es) | Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil. | |
| AR048927A1 (es) | Compuestos heterociclicos como inhibidores de proteinas de apoptosis (iap); composiciones farmaceuticas que los contienen y su uso en el tratamiento de una enfermedad proliferativa | |
| AR035174A1 (es) | Compuesto derivado de beta-aminoacido, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para tratar o prevenir trastornos inflamatorios y enfermedades mediadas por mmp, tnf y agrecansa y combinaciones de los mismos | |
| AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
| AR054232A1 (es) | Derivados de piridina -2- carboxamida como antagonistas de mglur5 | |
| AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
| AR069513A1 (es) | Derivados de amidas del acido 6,7-dihidro -5h-imidazo¿1,2-alfa]imidazol-3-carboxilico, y composiciones farmaceuticas que los contienen | |
| AR080187A1 (es) | Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen. | |
| AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
| AR062510A1 (es) | Derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos | |
| AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
| AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| AR057350A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas | |
| AR057086A1 (es) | Derivados de indol-3- il-carbonil-piperidina y piperazina, composicion farmaceutica y proceso de preparacion del compuesto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |